<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"> <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/"> <title>Nobilis Therapeutics Inc.</title> <link>https://www.globenewswire.com/rssfeed/organization/wvn5jjPcgL8a_vB3AMwwsQ==</link> <description>Contains the last 20 releases</description> <copyright>Copyright 2017, Nobilis Therapeutics Inc.</copyright> <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor> <lastBuildDate>Wed, 10 May 2017 09:00:00 GMT</lastBuildDate> <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/05/10/1006953/0/en/Nobilis-Therapeutics-and-Submersible-Systems-Partner-to-Create-a-Portable-Inhalation-Device-for-Administration-of-NBTX-001-a-Medical-Gas-based-Drug-Candidate.html</guid> <link>https://www.globenewswire.com/news-release/2017/05/10/1006953/0/en/Nobilis-Therapeutics-and-Submersible-Systems-Partner-to-Create-a-Portable-Inhalation-Device-for-Administration-of-NBTX-001-a-Medical-Gas-based-Drug-Candidate.html</link> <title>Nobilis Therapeutics and Submersible Systems Partner to Create a Portable Inhalation Device for Administration of NBTX-001, a Medical Gas-based Drug Candidate</title> <description><![CDATA[<p><span class="mw_region">PORTLAND, OR and HUNTINGTON BEACH, CA</span><span>--(Marketwired - May 10, 2017) - </span> <a href="http://www.nobilistx.com/" rel="nofollow" title="Nobilis Therapeutics">Nobilis Therapeutics</a>, Inc., a biotechnology company developing inhalation-based therapeutics to treat psychiatric and neurodegenerative disorders, and Submersible Systems, LLC., a leading manufacturer of rescue breathing devices, announced a partnership to create a portable hand-held inhalation device for administration of NBTX-001, a noble gas-based drug candidate. The creation of the first truly portable device will allow patients to receive NBTX-001 safely and independently. </p>]]></description> <pubDate>Wed, 10 May 2017 09:00 GMT</pubDate> <dc:identifier>1006953</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Nobilis Therapeutics</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:52 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/04/11/1006949/0/en/Nobilis-Therapeutics-Recruits-Internationally-Renowned-Xenon-Expert-to-Scientific-Advisory-Board.html</guid> <link>https://www.globenewswire.com/news-release/2016/04/11/1006949/0/en/Nobilis-Therapeutics-Recruits-Internationally-Renowned-Xenon-Expert-to-Scientific-Advisory-Board.html</link> <title>Nobilis Therapeutics Recruits Internationally Renowned Xenon Expert to Scientific Advisory Board</title> <description><![CDATA[<p> <span class="mw_region">SAN DIEGO, CA</span><span>--(Marketwired - April 11, 2016) - </span> Nobilis Therapeutics, today announced that Dr. Daqing Ma, MD, PhD, FRCA, a Macintosh Professor of Anesthesia and the Head of Anesthesia Research at the Imperial College of London (ICL), has joined its Scientific Advisory Board. </p>]]></description> <pubDate>Mon, 11 Apr 2016 19:54 GMT</pubDate> <dc:identifier>1006949</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Nobilis Therapeutics</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:52 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/03/29/1006946/0/en/Nobilis-Therapeutics-Signs-Exclusive-License-Agreement-with-Harvard-University-for-PTSD-Treatment.html</guid> <link>https://www.globenewswire.com/news-release/2016/03/29/1006946/0/en/Nobilis-Therapeutics-Signs-Exclusive-License-Agreement-with-Harvard-University-for-PTSD-Treatment.html</link> <title>Nobilis Therapeutics Signs Exclusive License Agreement with Harvard University for PTSD Treatment</title> <description><![CDATA[<p><em><p>Company Intends To Initiate Clinical Trial Using Non-Invasive Gas-Based Therapy</p></em></p><p> <span class="mw_region">SAN DIEGO, CA</span><span>--(Marketwired - March 28, 2016) - </span>Nobilis Therapeutics, Inc. announced today entry into an exclusive agreement with Harvard University's Partners Healthcare to license intellectual property surrounding the use of noble gas-containing mixtures as a treatment for Post-Traumatic Stress Disorder (PTSD). The agreement gives Nobilis Therapeutics the rights to the treatment of PTSD as well as of other psychiatric disorders.</p>]]></description> <pubDate>Tue, 29 Mar 2016 03:32 GMT</pubDate> <dc:identifier>1006946</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Nobilis Therapeutics</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:52 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/01/19/1006957/0/en/Nobilis-Therapeutics-Files-Patent-on-Noble-Gas-Treatment-for-Alzheimer-s-Disease.html</guid> <link>https://www.globenewswire.com/news-release/2016/01/19/1006957/0/en/Nobilis-Therapeutics-Files-Patent-on-Noble-Gas-Treatment-for-Alzheimer-s-Disease.html</link> <title>Nobilis Therapeutics Files Patent on Noble Gas Treatment for Alzheimer's Disease </title> <description><![CDATA[<p><em><p>Company Demonstrates Reduction of Neuroinflammation Through Administration of Proprietary Noble Gas-Based Therapeutic</p></em></p><p>SAN DIEGO, CA--(Marketwired - Jan 19, 2016) - <a rel="nofollow" href="http://www.nobilistx.com/" title="Nobilis Therapeutics">Nobilis Therapeutics</a>, a biotechnology company dedicated to clinical development of Noble Gas-based medical interventions, announced today filing of a patent demonstrating inhibition of neuroinflammation using its proprietary product candidate NBTX-001. Experimental in vitro data presented in the patent demonstrates that treatment with <a rel="nofollow" href="http://www.nobilistx.com/" title="NBTX-001">NBTX-001</a> resulted in suppression of inflammatory mediators, as well as blocked maturation of important immunological effector cells termed dendritic cells. </p>]]></description> <pubDate>Tue, 19 Jan 2016 06:47 GMT</pubDate> <dc:identifier>1006957</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Nobilis Therapeutics</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:52 GMT</dc:modified> </item> </channel> </rss>